Which has higher valuation and earnings, TIL or WHWK?

Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Whitehawk Therapeutics N/A N/A -$20.60M -$1.12 N/A

Is TIL or WHWK more profitable?

Instil Bio's return on equity of -39.76% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Whitehawk Therapeutics N/A -58.46% -53.81%

Is PYXS or TIL more profitable?

Instil Bio's return on equity of -39.76% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Instil Bio N/A -39.76% -22.38%

Which has preferable earnings and valuation, TIL or NBP?

I-Mab has higher revenue and earnings than Instil Bio. I-Mab is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A I-Mab $3.89M 52.62 -$46.27M -$0.36 N/A

Is TIL or NBP more profitable?

I-Mab's return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% I-Mab N/A N/A N/A

Which has preferable earnings & valuation, TIL or MDWD?

MediWound has higher revenue and earnings than Instil Bio. MediWound is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A MediWound $14.48M 12.28 -$23.88M -$2.26 N/A

Is TIL or MDWD more profitable?

Instil Bio has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Instil Bio's return on equity of -39.76% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% MediWound -180.30% -67.22% -31.87%

Instil Bio (TIL) Competitors

$7.41 0.00 (0.00%)

As of 04:00 PM Eastern

Compare

TIL vs. WHWK, PYXS, PLX, NBP, and MDWD

Should you buy Instil Bio stock or one of its competitors? Instil Bio's main competitors and comparable companies include Whitehawk Therapeutics (WHWK), Pyxis Oncology (PYXS), Protalix BioTherapeutics (PLX), I-Mab (NBP), and MediWound (MDWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Instil Bio compare to Whitehawk Therapeutics?

Instil Bio (NASDAQ:TIL) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 47.0% of Instil Bio shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Instil Bio currently has a consensus target price of $66.00, indicating a potential upside of 809.09%. Whitehawk Therapeutics has a consensus target price of $8.20, indicating a potential upside of 80.22%. Given Instil Bio's higher probable upside, equities analysts plainly believe Instil Bio is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Whitehawk Therapeutics had 7 more articles in the media than Instil Bio. MarketBeat recorded 7 mentions for Whitehawk Therapeutics and 0 mentions for Instil Bio. Whitehawk Therapeutics' average media sentiment score of 0.63 beat Instil Bio's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Instil Bio	Neutral
Whitehawk Therapeutics	Positive

Instil Bio's return on equity of -39.76% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Whitehawk Therapeutics	N/A	-58.46%	-53.81%

Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A

Summary

Whitehawk Therapeutics beats Instil Bio on 7 of the 13 factors compared between the two stocks.

How does Instil Bio compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Instil Bio has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	17.51	-$79.62M	-$1.31	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Pyxis Oncology currently has a consensus price target of $7.50, indicating a potential upside of 95.82%. Instil Bio has a consensus price target of $66.00, indicating a potential upside of 809.09%. Given Instil Bio's higher possible upside, analysts clearly believe Instil Bio is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Pyxis Oncology had 4 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for Pyxis Oncology and 0 mentions for Instil Bio. Pyxis Oncology's average media sentiment score of 0.63 beat Instil Bio's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Positive
Instil Bio	Neutral

Instil Bio's return on equity of -39.76% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Instil Bio	N/A	-39.76%	-22.38%

Pyxis Oncology has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

Summary

Instil Bio beats Pyxis Oncology on 8 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Instil Bio has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Instil Bio	N/A	-39.76%	-22.38%

Protalix BioTherapeutics has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Protalix BioTherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 383.87%. Instil Bio has a consensus price target of $66.00, suggesting a potential upside of 809.09%. Given Instil Bio's higher possible upside, analysts plainly believe Instil Bio is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Protalix BioTherapeutics has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.62	$8.31M	$0.18	13.78
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for Instil Bio. Protalix BioTherapeutics' average media sentiment score of 1.49 beat Instil Bio's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protalix BioTherapeutics	Positive
Instil Bio	Neutral

Summary

Protalix BioTherapeutics beats Instil Bio on 9 of the 15 factors compared between the two stocks.

How does Instil Bio compare to I-Mab?

Instil Bio (NASDAQ:TIL) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

I-Mab has higher revenue and earnings than Instil Bio. I-Mab is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
I-Mab	$3.89M	52.62	-$46.27M	-$0.36	N/A

In the previous week, Instil Bio's average media sentiment score of 0.00 equaled I-Mab'saverage media sentiment score.

Company	Overall Sentiment
Instil Bio	Neutral
I-Mab	Neutral

I-Mab's return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
I-Mab	N/A	N/A	N/A

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Instil Bio has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

Instil Bio currently has a consensus price target of $66.00, indicating a potential upside of 809.09%. I-Mab has a consensus price target of $9.00, indicating a potential upside of 408.47%. Given Instil Bio's higher possible upside, analysts plainly believe Instil Bio is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

I-Mab beats Instil Bio on 7 of the 12 factors compared between the two stocks.

How does Instil Bio compare to MediWound?

Instil Bio (NASDAQ:TIL) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

MediWound has higher revenue and earnings than Instil Bio. MediWound is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
MediWound	$14.48M	12.28	-$23.88M	-$2.26	N/A

Instil Bio currently has a consensus target price of $66.00, indicating a potential upside of 809.09%. MediWound has a consensus target price of $34.00, indicating a potential upside of 145.84%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Instil Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, MediWound has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 47.0% of Instil Bio shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, MediWound had 2 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for MediWound and 0 mentions for Instil Bio. MediWound's average media sentiment score of 0.34 beat Instil Bio's score of 0.00 indicating that MediWound is being referred to more favorably in the news media.

Company	Overall Sentiment
Instil Bio	Neutral
MediWound	Neutral

Instil Bio has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Instil Bio's return on equity of -39.76% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
MediWound	-180.30%	-67.22%	-31.87%

Summary

Instil Bio beats MediWound on 8 of the 15 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TIL vs. The Competition

Export

Metric	Instil Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$49.22M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.03	9.13	269.75	24.73
Price / Sales	N/A	1,274.20	652.34	108.63
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.43	17.66	11.27	6.42
Net Income	-$71.37M	-$13.25M	$3.45B	$347.12M
7 Day Performance	0.55%	5.36%	3.56%	2.48%
1 Month Performance	-5.71%	-1.74%	-0.58%	-1.04%
1 Year Performance	-74.06%	61.36%	77.52%	23.22%

Instil Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TIL Instil Bio	1.639 of 5 stars	$7.41 flat	$66.00 +790.7%	-73.5%	$50.24M	N/A	N/A	410	Upcoming Earnings
WHWK Whitehawk Therapeutics	2.4606 of 5 stars	$4.14 +4.5%	$8.20 +98.1%	+172.0%	$195.83M	$7.14M	N/A	21	Earnings Report Analyst Upgrade
PYXS Pyxis Oncology	3.1673 of 5 stars	$3.16 +3.9%	$7.50 +137.3%	+251.9%	$192.60M	$13.86M	N/A	60	Upcoming Earnings
PLX Protalix BioTherapeutics	3.2333 of 5 stars	$2.37 +2.2%	$12.00 +406.3%	+59.7%	$190.96M	$76.38M	N/A	200
NBP I-Mab	1.9882 of 5 stars	$1.65 +2.5%	$9.00 +445.5%	N/A	$186.19M	$3.89M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Instil Bio (TIL) Competitors

TIL vs. WHWK, PYXS, PLX, NBP, and MDWD

How does Instil Bio compare to Whitehawk Therapeutics?

Summary

How does Instil Bio compare to Pyxis Oncology?

Summary

How does Instil Bio compare to Protalix BioTherapeutics?

Summary

How does Instil Bio compare to I-Mab?

Summary

How does Instil Bio compare to MediWound?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Instil Bio (TIL) Competitors

TIL vs. WHWK, PYXS, PLX, NBP, and MDWD

How does Instil Bio compare to Whitehawk Therapeutics?

Do institutionals & insiders believe in TIL or WHWK?

Which has more risk and volatility, TIL or WHWK?

Do analysts prefer TIL or WHWK?

Does the media refer more to TIL or WHWK?

Is TIL or WHWK more profitable?

Which has higher valuation and earnings, TIL or WHWK?

Summary

How does Instil Bio compare to Pyxis Oncology?

Do insiders & institutionals believe in PYXS or TIL?

Which has better valuation and earnings, PYXS or TIL?

Do analysts rate PYXS or TIL?

Does the media prefer PYXS or TIL?

Is PYXS or TIL more profitable?

Which has more risk and volatility, PYXS or TIL?

Summary

How does Instil Bio compare to Protalix BioTherapeutics?

Is PLX or TIL more profitable?

Which has more risk and volatility, PLX or TIL?

Do institutionals & insiders have more ownership in PLX or TIL?

Do analysts prefer PLX or TIL?

Which has higher earnings & valuation, PLX or TIL?

Does the media refer more to PLX or TIL?

Summary

How does Instil Bio compare to I-Mab?

Which has preferable earnings and valuation, TIL or NBP?

Does the media refer more to TIL or NBP?

Is TIL or NBP more profitable?

Do institutionals and insiders believe in TIL or NBP?

Which has more risk and volatility, TIL or NBP?

Do analysts rate TIL or NBP?

Summary

How does Instil Bio compare to MediWound?

Which has preferable earnings & valuation, TIL or MDWD?

Do analysts prefer TIL or MDWD?

Which has more risk and volatility, TIL or MDWD?

Do institutionals & insiders hold more shares of TIL or MDWD?

Does the media refer more to TIL or MDWD?

Is TIL or MDWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools